3.5500 0.00 (0.14%)
After hours: 5:47PM EDT
|Bid||3.5400 x 3100|
|Ask||3.5500 x 3100|
|Day's range||3.5073 - 3.7200|
|52-week range||1.4000 - 6.0700|
|Beta (5Y monthly)||0.52|
|PE ratio (TTM)||N/A|
|Earnings date||05 Nov 2020 - 09 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.00|
Shares of Amyris (NASDAQ: AMRS) gained over 12% today after the company announced it had signed a binding term sheet with the Infectious Disease Research Institute (IDRI) to collaborate on a SARS-CoV-2 vaccine candidate. Specifically, IDRI will develop a vaccine candidate based on its RNA vaccine platform, while Amyris will supply squalene for use in the vaccine adjuvant.
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Amyris, Inc.
INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims Against Amyris, Inc.